Introduction
Lyme borreliosis is the most common vector-borne bacterial infection in the northern hemisphere, caused by the spirochete Borrelia burgdorferi sensu lato complex.(Bb.) Erythema migrans, a skin lesion, is the most common manifestation. Infection of the nervous system is reported in 10-20% in American and European studies (1, 2) .
European Lyme neuroborreliosis (LNB) often presents with a subacute painful lymphocytic meningoradiculitis (Bannwarth syndrome) with or without paresis in the abdominal wall, the limbs, or muscles innervated by cranial nerves. Central nervous system (CNS) involvement as encephalitis, myelitis, and vasculitis is rare (3) .
Most patients with LNB experience marked improvement in neurological symptoms within weeks to a few months after antibiotic treatment, but years after treatment 10-50% report persisting or new symptoms including fatigue, paresthesias, concentration difficulties, myalgias, arthralgias, and headache (2, (4) (5) (6) (7) . Remaining complaints after adequately treated Bb infections are often named post-Lyme disease syndrome (PLD). The prevalence and impact of PLD is debated because similar symptoms are common in the general population, and there are few controlled studies on the issue (8) . In two recent publications, one American study of long-term outcome after erythema migrans and one Swedish study of 6-month outcome after pediatric LNB, subjective symptoms were not more frequent among patients than among non-infected controls (9, 10) . Our aim was to investigate the long-term impact of LNB on health-related Quality of Life (QoL) in a controlled Objectives -The prognosis after Lyme neuroborreliosis (LNB) is debated. The aim of this study was to assess health-related Quality of Life (QoL) and neurological symptoms 30 months after treatment in European patients with LNB. Materials and methods -In a prospective case-control designed study, we investigated 50 well-characterized patients with LNB who had participated in a treatment trial for LNB 30 months earlier and 50 matched control persons with the health QoL questionnaire Short-Form 36 (SF-36), the Fatigue Severity Scale (FSS), the Montgomery and Å sberg Depression Rating Scale (MADRS), the Starkstein Apathy Scale (SAS), and the Mini Mental State (MMS). Clinical and demographic data were collected by semistructured interviews and clinical neurological examination. ResultsLyme neuroborreliosis-treated patients scored lower than control persons in the SF-36 domains physical component summary (PCS) (44 vs 51 P < 0.001) and mental component summary (MCS) (49 vs 54 P = 0.010). They also scored lower than control persons in all the SF-36 subscales, except for bodily pain, and on FSS (3.5 vs 2.1 P < 0.001), but not on MMS (28 vs 29 P = 0.106). There was a difference in MADRS (3.1 vs 0. 8 P = 0.003) and SAS (13 vs 11 P = 0.016), but the scores were low in both groups. Fatigue was the most frequently reported symptom among LNB-treated patients (50%). Patients who reported complete recovery (56%) after LNB had similar QoL scores as the controls. Conclusion -European persons treated for LNB have poorer health-related QoL and have more fatigue than persons without LNB.
study of prospectively followed well-characterized adult European patients with LNB.
Materials and methods

Study design
A prospective case-control study.
Subjects
In the period 2004-2008, 102 consecutive adult patients with LNB from nine different hospitals in southern Norway were included in a treatment trial comparing 14-day courses of intravenous ceftriaxone (2 g daily) and oral doxycycline (200 mg daily). The study design, population, and inclusion criteria are described elsewhere (11) . We invited the patients with LNB from two of the nine hospitals in the treatment trail to participate in our follow-up study 30 months (range 27-34) after treatment. The patients were living in the same geographic region, namely the high endemic region of Agder County. They were invited by letter, and non-responders were phoned once. The assessments took place in the Department of Neurology at Sørlandet Hospital and were made by one experienced neurologist. Patients classified as having definite or possible LNB according to predefined criteria (Table 1) were eligible.
Of 59 eligible persons, nine refused to participate, and 50 were included and analyzed. Pretreatment clinical presentation in these 50 patients was complete or partial Bannwarth syndrome (n = 40), plexopathy (n = 1), ataxia (n = 2), myelopathy (n = 1), confusion (n = 1), and subjective symptoms (myalgia, asthenia, headache, joint pain, malaise) (n = 5). Thirty-four (68%) were classified as definite and 16 (32%) as possible LNB. Twenty-six (52%) were treated with oral doxycycline and 24 (48%) with IV ceftriaxone.
Each LNB-treated patient invited a control person at the time of follow-up, matched for age, education level, and gender. If a patient failed to bring a control person, another was asked to bring two. The only exclusion criteria for the controls were previous acknowledged LNB. Characteristics of the study participants assessed at start time of the follow-up study are shown in Table 2 . One patient had multiple sclerosis (MS), (MS was known for years, and the neurological deficits caused by MS did not change after antibiotic treatment for LNB) and one had ParkinsonÕs disease. (The symptoms and neurological findings caused by ParkinsonÕs disease did not disappear after LNB treatment, except that the tremor became less prominent.) In those two patients, the neurological findings attributed to LNB were new and accompanied by typical laboratory findings, and thus the criteria for definite LNB were fulfilled. The cancer disease observed in both groups was treated and cured 10-20 years earlier except for two patients, one who had a stable frontal astocytoma and one patient who was diagnosed with an advanced cancer prostate between the treatment for LNB and follow-up.
All persons in the LNB group and control group gave written informed consent. The study was approved by the Regional Committee for Medical Research Ethics in Southern Norway and by the Norwegian Data Inspectorate. This trial is a follow-up study on the treatment trial registered with ClinicalTrials.gov number NCT00138801.
Variables
At inclusion in the follow-up study, both groups answered the Norwegian translation of SF-36 questionnaire, a short generic, 36-item questionnaire which measures eight multi-item dimensions covering functional status, well-being and over-all evaluation of health, the Fatigue Severity Scale (FSS), the Montgomery and Å sberg Depression Rating Scale (MADRS), the Starkstein Apathy Scale (SAS), and the Mini Mental State (MMS). Clinical and demographic variables were assembled during semi-structured interviews and clinical neurological examination. The patients were also tested for tick-borne encephalitis virus (TBE) infection. All participants were asked the following: Do you have any other diseases? Do you have, or have you previously had, psychological diseases that made it necessary to use pharmacological therapy, consult a therapist or take sick leave? Is fatigue an every-day problem for you? Did you recover completely from the LNB? In the LNB group, we reviewed individual hospital records to confirm the past medical history, but out of ethical reasons, we did not do that in the control group.
Our primary outcomes were the two mean SF-36 summary measures; physical component summary (PCS) and mental component summary (MCS) scores. PCS is summarized from the four physical health subscores; physical functioning (PF), role physical (RP), bodily pain (BP), and general health (GH); and MCS from the four mental health subscores; vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH). The score range for the subscores is 0 -100, with 100 as the best score. It was not possible to calculate PCS in one control and one case or MCS in one case because of missing data on three of the SF-36 subscores. Secondary endpoints were the eight subscores of the SF-36, fatigue score [FSS, score range 0-9, with 4 regarded as significant fatigue (12) and 5 as severe fatigue (13)], depression score (MADRS score range 0-60,), apathy score (SAS, score range 0-42), cognition score (MMS, score range 0-30), and subjective reported symptoms.
Sample size
When taking into consideration earlier studies using SF-36 as an outcome measure in neurological diseases, we decided, in advance of study start, that a group difference of 7% in the SF-36 PCS and MCS between the two groups would be of clinical interest to detect (14) . With a two-sided test and a significance level of 0.05, 36 participants were required in each group to reject a null hypothesis of no difference with 80% power. To compensate for dropouts and non-evaluable tests, we planned to enroll 50 persons.
Statistical analysis
The statistical software spss version 16 was used for all analyses.
The groups were compared by using student ttest (unpaired continuous data) and chi-square test (unpaired categorical data). P values <0.05 were regarded as statistically significant.
The results are reported as mean scores with standard deviations or proportions.
Results
Quality of life
The results of primary and secondary outcomes are shown in Table 3 . The primary outcome QoL in terms of SF-36 mean sum scores in PCS and MCS was lower among persons treated for LNB when compared to matched controls, with a difference of 14% and 9%, respectively, indicating a poorer QoL. The LNB-treated patients and controls differed with respect to all subscores of SF-36 except for bodily pain.
Fatigue
Mean FSS scores are shown in Table 3 . Twentyone (42%) LNB-treated patients and five controls (10%) scored ‡4 points on FSS (significant fatigue), and 13 LNB-treated persons (26%) and two controls (4%) (one with post-polio and one with chronic disabling cluster headaches) scored ‡5 points on FSS (severe fatigue). Twenty-five (50%) persons in the LNB group when compared to 8 (16%) in the control group (P = 0.001) answered that fatigue was an every-day problem for them.
Depression, apathy and cognition
The MADRS and SAS scores differed in the two groups, but were low in both groups, one patient scored 21 and one 16 on the MADRS scale (0-60). MMS scores were comparable.
Neurological findings
Fourteen (28%) LNB-treated patients had neurological findings [facial palsy n = 3, reduced hearing
European LNB, quality of life n = 1, reduced sensibility in the face n = 3, anisocoria n = 1, tremor n = 2, ataxia n = 2, nystagmus n = 2, radiculopathy n = 6, arm ⁄ leg paresis n = 4. Tick-borne encephalitis virus antibody analyses at treatment baseline were carried out in 20 patients and were positive for IgG in one and negative for IgM in all. At follow-up, TBE antibodies were analyzed in all patients and two more had a positive IgG. One of them scored lower than the mean on the PCS and MCS (mental component summary), and the two others scored higher than the mean.
Discussion
We found that patients treated for LNB 30 months earlier had poorer health-related QoL when compared to matched controls, in one terms of lower mean scores in the SF-36 domains of PCS (physical component summary) and MCS.
Persisting complaints after treatment for Lyme disease is a matter of much discussion with respect to prevalence, clinical picture, impact on QoL, and pathogenesis (15) . Previous studies on QoL after treated LNB are limited and give indefinite results. Shadick and co-authors found, in a retrospective controlled cohort study, that persons treated for Lyme disease 6 years earlier had a poorer functional outcome assessed by SF-36 owing to pain, more symptoms of memory impairment, but similar performance on physical examination and neurocognitive tests as control persons (16) . In contrast, Seltzer et al. (17) found no differences in SF-36 scores between patients diagnosed with Lyme disease 1-11 years earlier and age-matched controls. Both studies included a heterogeneous group of patients, and both were carried out in the United States where Lyme disease is characterized by a different clinical phenotype and bacteriological genotype than in Europe. To our knowledge, no European studies address QoL after treatment for LNB.
Further analyses of the symptom profile in our LNB-treated patients showed that they scored lower on all the SF-36 subscores except on bodily pain, and they reported more fatigue and memory problems and concentration difficulties more often than matched controls. We could not, however, confirm any difference in cognition in the two groups assessed by MMS, but this is considered to be a rough screening questionnaire, and further neurocognitive investigations will be the issue in a later publication. In contrast to results from American studies (18), pain was not more common among LNB-treated patients than among controls neither assessed by direct question nor by SF-36. This difference may reflect different patient populations and possibly different tissue affinity of the different Bb species (19) . Fifty-six percent of the LNB-treated patients reported complete recovery. This is in accordance with previous reports of 50-90% recovery after treatment for LNB (2, 4, 7, 20) . Subgroup analyses showed that LNB-treated patients who reported complete recovery had similar QoL as control persons, while those with persistent complaints had a mean PCS score of 37, MCS of 47, and FSS of 4.8, comparable to the scores in two trials of prolonged antibiotic treatment in patients suffering from persistent complaints after any type of Lyme borreliosis reporting mean baseline PCS of 34, MCS of 44 (14) , and PCS of 37, MCS of 44 and FSS of 5.2 (21), respectively. In another post-Lyme treatment trial, where one inclusion criterion among others was FSS score ‡4, mean baseline FSS score was 5.7 (22) .
There were no differences in the mean PCS or MCS scores between patients with possible LNB and patients with definite LNB or between patients treated with IV ceftriaxone and patients treated with oral doxycycline. These findings confirm results at an earlier phase of the study (6, 11) .
The underlying pathogenesis of PLD is widely debated, but still unknown. The burden of fatigue after treated LNB seems to be comparable to that reported in other neurological diseases as MS (23) and ParkinsonÕs disease (24) and to that reported after stroke, Guillain-Barre syndrome or traumatic brain injury (25) (26) (27) . Fourteen (28%) of our LNBtreated patients had persisting neurological findings. This frequency is comparable to reports from Sweden and Denmark of 12% and 5% disabling sequelae 5 years and 33 months after treatment for LNB, respectively (2, 28) . Although the neurological findings in our LNB-treated patients were moderate, some probably gave physical disability, as LNB-treated patients with remaining neurological findings scored lower on PCS and higher on FSS when compared to those without.
Psychiatric comorbidity has been suggested as a cause of post-Lyme disease syndrome (29) . We did not find any difference in psychiatric comorbidity between LNB-treated patients and controls in this study, and the depression and apathy scores were low in both groups. Nor were there any differences in depression scores between the patients with LNB reporting incomplete recovery and the patients reporting complete recovery after treatment. It is also possible that reports from media about dangerous consequences of LNB can form expectations of poor health and influence the answers given on the questionnaires in this study and thereby affect QoL.
The strength of our study is a well-defined patient group, a matched control group, and standardized questionnaires. Because the patients selected their controls themselves, this method could potentially lead to a selection bias toward more healthy controls. However, the fact that coexisting diseases were found to be equally frequent among patients and controls suggest that there was not a bias for a better health history among controls.
Conclusion
This first controlled study of QoL in European patients with LNB clearly demonstrates that mean physical and mental health QoL are reduced in a group of patients treated for LNB 30 months earlier when compared to a group of matched controls. Twenty-eight percent of the LNB-treated patients had minor neurological findings. Fatigue was the dominating symptom, while depression, apathy, and pain did not seem to be a clinical significant problem. Further studies should be carried out to elucidate the underlying pathogenesis and the total impact on long-term outcome of Lyme disease.
